Skip to main content

Table 1 Study characteristics of the included studies

From: Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

Author Year Design Patients (n) Inclusion Neoadjuvant therapy regimen Scanner FDG dose (MBq) Uptake time (min) Median follow-up (months)
Akimoto [12] 2018 P 130 Not specified Anthracycline + taxane-based PET/CT 3.7/kg 60 NR
Champion [13] 2015 P 23 Inflammatory Anthracycline ± taxane-based PET/CT 4–5/kg 73 ± 21 76 ± 27
Chen [14] 2017 R 86 Stage II–III Anthracycline ± taxane-based PET/CT 259–555 60 71 (8–118)
Dunnwald [15] 2011 P 75 LABC Anthracycline ± taxane-based PET 218–399 60 DFS: 50 (1–156)
OS: 60 (7–161)
Emmering [16] 2008 P 40 LABC Anthracycline-based PET 370 60–90 60
Garcia Vicente [17] 2016 P 132 Not specified Anthracycline ± taxane-based PET/CT 370 60 35.5* (12–62)
Groheux [18] 2015 P 82 ER+/HER2−, stage II–III Anthracycline + taxane-based PET/CT 5/kg 60 35 (10–71)
Groheux [19] 2016 R 78 TN, stage II–III Anthracycline + taxane-based; dose-intense anthracycline-based PET/CT 5/kg 60 34 (3–85)
Humbert [20] 2014 P 42 HR+/HER2−, stage II–IIIA Anthracycline ± taxane-based PET or PET/CT PET: 2/kg; PET/CT: 5/kg 60 64.2 (11.5–93.2)
Humbert [21] 2016 P 46 TN, Stage II–III Anthracycline ± taxane-based PET/CT 5/kg 60 30 (6–73)
Hyun [22] 2015 R 167 Stage II–III Anthracycline ± taxane-based PET/CT 5.5/kg 60 19 (3–85)
Ishiba [23] 2015 R 83 Not specified Anthracycline ± taxane-based PET/CT 3.7/kg NR 50
Jung [24] 2010 P 66 Stage II–III Anthracycline ± taxane-based PET 370–555 60 61.5 (13.5–71.8)
Kim [25] 2016 R 139 Stage II–III Anthracycline + taxane-based PET/CT 5/kg 60 26.2 ± 16.1*
Kitajima [26] 2018 R 56 Not specified Anthracycline ± taxane-based PET/CT 3–4/kg 60 No recurrence: 29.1 (12.3–96.4)
Recurrence: 19.2 (11.4–37.4)
Kiyoto [27] 2016 R 32 TN, stage II–III Anthracycline ± taxane-based PET/CT 3/kg 90 39.0 (5.8–91.2)
Kolesnikov-Gauthier [28] 2012 P 60 Non-inflammatory, M0 Anthracycline + taxane-based PET 370 60 43 (14–68)
Lee [29] 2016 R 87 Stage II–III Anthracycline-based PET or PET/CT 5.5/kg 60 61 (10–107)
Lian [30] 2020 R 92 Not specified Anthracycline ± taxane ± platinum-based PET/CT 7.4/kg 60 No recurrence: 48.7 (20.6–84.1)
Recurrence: 38.6 (11.4–82.7)
Lim [31] 2014 P 54 Stage II–III Anthracycline + taxane-based PET/CT 7.4/kg 60 38 (25–45)
Zucchini [32] 2013 R 60 Early, LABC, or oligometastatic Anthracycline + taxane-based PET/CT 5.3/kg 60–70 36.6 (8–79)
  1. *mean
  2. CT computed tomography, DFS disease-free survival, ER oestrogen receptor, HR hormone receptor. HER2 human epidermal growth factor receptor 2, LABC locally advanced breast cancer, OS overall survival, P prospective, PET positron emission tomography, R retrospective, TN triple-negative